乳腺癌新辅助化疗PCR与生存获益的研究进展  

A review of the relationship of pathological complete response and long-term clinical benefit in breast cancer with neoadjuvant chemotherapy treatment

作　　者：李晓瑛[1] 曹彧[1] 王玉颖[1] 金锋[1] 

机构地区：[1]中国医科大学附属第一医院乳腺外科一病区,辽宁沈阳110001

出　　处：《现代肿瘤医学》2017年第3期502-505,共4页Journal of Modern Oncology

摘　　要：乳腺癌的治疗理念已经从局部疾病转变为全身疾病,随着近几年的研究,新辅助化疗的治疗方式被应用的越来越广泛,它不仅可以缩小肿瘤的大小,达到可手术切除的目的,而且可以使有保乳意愿的年轻患者实现保乳,同时也间接的起到体内药敏试验的效果,更好地指导手术后的化疗方案选择。新辅助化疗后病理完全缓解被认为是长期生存获益的替代指标,受到越来越多的关注。The theory of the treatment was transformed from a local disease into a systematic disease in breast canc-er. As the researches was progressing in recent years,neoadjuvant chemotherapy treatment is now being used more widely. It can not only reduce the size of tumor to achieve the purpose of surgical resection,but also make the young patients with reserved breast surgery. In addition,neoadjuvant chemotherapy treatment has the effect of drug sensitive test in vivo to guide postoperative chemotherapy scheme selection. It was payed more attention to pathological complete response has been proposed as a surrogate endpoint for prediction of long - term clinical benefit.

关 键 词：新辅助化疗 病理完全缓解(PCR) 无进展生存期 总生存期 

分 类 号：R737.9[医药卫生—肿瘤]